Intuitive Surgical reports third-quarter results. Intuitive Surgical stock falls 7.22 percent

Published on 10/21/2026 at 10:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue rose 22.00 percent to USD 3.05 billion. Intuitive Surgical stock costs EUR 359.85 on October 21, 2026, 7.22 percent below Xetra close.

Revenue and margin outlook

Third-quarter revenue reached USD 3.05 billion on October 20, 2026.
Full-year da Vinci procedure growth is forecast at 14 percent to 15 percent.
Intuitive Surgical stock trades at EUR 359.85 at 10:37 a.m. CEST at Lang & Schwarz on October 21, 2026, 7.22 percent below the Xetra close of October 20, 2026.

Schwarzweiß-Reportagefoto eines Chirurgen an der Konsole während einer robotergestützten Operation — Dokumentarische Schwarzweiß-Reportage aus dem OP-Saal illustriert Intuitive Surgical Inc. (US46120E6023) und den Arbeitsalltag der Chirurgie-Robotik, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) reported third-quarter revenue of USD 3.05 billion on October 20, 2026, up 22.00 percent from the prior-year quarter, while its stock fell 7.22 percent below the Xetra close. In its Intuitive release, the company reported GAAP net income of USD 523 million, or USD 1.49 per diluted share, after a USD 450 million pretax litigation charge.

Revenue growth meets a legal charge

The quarter delivered strong operating growth despite the settlement expense. Instruments and accessories revenue rose 18.00 percent to USD 1.80 billion, while systems revenue reached USD 769 million, according to Morningstar.

Adjusted earnings per share came to USD 3.00, compared with a USD 2.65 consensus estimate, while revenue exceeded the USD 2.91 billion estimate by USD 140 million. The comparison matters because the GAAP result was reduced by the litigation charge, whereas the adjusted figure captures the operating performance more directly.

What does the margin outlook mean?

Management narrowed its full-year 2026 da Vinci procedure growth outlook to 14 percent to 15 percent from 13.5 percent to 15.5 percent. It also forecast a non-GAAP gross profit margin of 68.7 percent to 69.3 percent, compared with the previous 68 percent to 69 percent range, and maintained non-GAAP operating expense growth of 11 percent to 13 percent, as reported by AlphaStreet.

Procedure growth remained broad based. Worldwide da Vinci and Ion procedures increased 15 percent from the third quarter of 2025, and Intuitive placed 546 da Vinci systems versus 427 a year earlier. The company also repurchased 7.8 million shares for USD 2.94 billion during the quarter.

Stock reaction after the results

The market reaction contrasted with the operating figures. Intuitive Surgical stock was trading at EUR 359.85 at Lang & Schwarz on October 21, 2026, at 10:37 a.m. CEST, down 7.22 percent versus the Xetra close of October 20, 2026 at EUR 387.85. The US listing is on Nasdaq under ticker ISRG, and the stock had closed at USD 438.00 on October 20, 2026, before the after-hours reaction.

For investors, the key tension is visible in the numbers: revenue and adjusted earnings expanded, but the litigation charge reduced GAAP profit and the new margin outlook still includes tariff effects. The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.